Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$15.67 USD

15.67
8,845,931

+0.47 (3.09%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $15.63 -0.04 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kevin Cook headshot

Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel

by Kevin Cook

Two women will share the Nobel prize for a gene editing technology that will change the world.

Zacks Equity Research

CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

by Zacks Equity Research

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.

Kevin Cook headshot

CRISPR Stocks: Buy or Trade?

by Kevin Cook

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 11.59% and 72.13%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q2 Earnings Expected to Decline

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Regeneron Gets FDA Nod for Dupixent 300 Mg Pre-Filled Pen

by Zacks Equity Research

Regeneron (REGN) wins FDA approval for a 300-mg, single-dose, pre-filled pen for asthma drug, Dupixent.

Zacks Equity Research

Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%

by Zacks Equity Research

Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

Zacks Equity Research

Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.

Zacks Equity Research

Regeneron Expands Deal With Intellia for Hemophilia Treatments

by Zacks Equity Research

Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.

Zacks Equity Research

Intellia Therapeutics Inc (NTLA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics Inc (NTLA) delivered earnings and revenue surprises of -61.54% and -46.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?